The Patent Finder

Terms ending in 2035

Pharmacyclics, Inc.

Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,580,416Inhibitors of Bruton's Tyrosine Kinase
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 9,730,938Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 10,898,461Novel Salts of 3-[(DIMETHYLAMINO)METHYL]-N-{2-[4-(HYDROXYCARBAMOYL) PHENOXY]ETHYLI-1-Benzofuran-2-Carboxamide, Related Crystalline Forms, Method for Preparing the Same and Pharmaceutical Compositions Containing the Same
In force
 · Medium confidence
Pharmacyclics LLCIn forceMedium confidence
US 10,226,466Methods of Treating Fibrosis
In force
 · Medium confidence
Pharmacyclics LLCIn forceMedium confidence
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited